Study Highlights:
- New oral blood thinners are easier to take than the older drug warfarin, but there is no clear method to reverse the action and prevent dangerous bleeding if a person suffers an accident or needs emergency surgery.
- In a laboratory test of reversal methods, three different approaches were able to alter the anticoagulant action of apixaban.
- The research is part of the American Heart Association's Emerging Science Series, a free online webinar presentation. View the webinar at www.scientificsessions.org/emergingscience.
EMBARGOED UNTIL Noon CT/1 pm ET, Wednesday, June 20, 2012
DALLAS, June 20, 2012 (GLOBE NEWSWIRE) -- Three approaches may reverse the blood thinning action of the new oral anticoagulant drug apixaban when a person suffers an accident or needs emergency surgery, according to laboratory research presented in the American Heart Association's Emerging Science Series webinar.
Some of the therapeutic strategies that reverse the blood thinner warfarin may be effective with newer oral anticoagulants such as apixaban and rivaroxaban. The newer drugs require less frequent blood tests, have fewer interactions with foods and other medications and doses are less variable.
"Despite these advantages, there is one common side effect of all blood thinners that can be severe — excess bleeding," said Gines Escolar, M.D., Ph.D., study author and associate professor of hematology at the University of Barcelona in Spain.
"If you have an accident or need emergency surgery, doctors have three ways to reverse warfarin that work in a matter of minutes to hours. In contrast, there is little information on how best to reverse the effects of newer anticoagulants, which can take 10-18 hours."
Warfarin blocks vitamin K. So if excess bleeding occurs, the drug's action can be reversed by administering the vitamin. When quick reversal is urgent with warfarin, other faster steps are sometimes taken. Researchers tested these steps in the preliminary study.
Blood clotting agents can potentially counteract the effect of blood thinners. In the lab, researchers added a high dose of apixaban (200 nanograms per milliliter) to blood from healthy donors. Then, they tested the blood-clotting response when three clotting agents were added: prothrombin complex concentrates (PCCs, 50 IU/kg), activated prothrombin complex concentrates (aPCCs, 75 IU/kg) and recombinant Factor VII (rFVIIa, 270 ug/kg). They found:
- PCC and aPCC seemed more efficient than rFVIIa at restoring the generation of thrombin, an enzyme important in blood clotting.
- rFVIIa was the quickest to produce a compact blood clot, followed by aPCC and PCC.
- rFVIIa was most effective in studies with blood circulating through a damaged blood vessel, followed by PCC and aPCC.
"The good news is that the various lab tests applied indicate that these approaches may reverse the effects of apixaban," Escolar said. "But, even with the favorable results in perfusion studies using a damaged vessel, we're far from knowing what will work best in a bleeding patient. Resolving efficacy and safety issues will require a clinical trial."
Apixaban is approved in Europe for preventing blood clots in adults after knee or hip replacement surgery. In the United States, a Federal Drug Administration application is under review for using apixaban to prevent stroke in people with atrial fibrillation.
Co-authors are: Eduardo Arellano-Rodrigo, M.D., Ph.D.; Juan Carlos Reverter, M.D., Ph.D.; Jaume Villalta, M.D., Ph.D.; Veronica Sanz, MLT ; Patricia Molina, MLT; Maribel Diaz-Ricart, Ph.D.; and Ana Maria Galan, M.D., Ph.D. Author disclosures are on the abstract.
Bristol-Myers Squibb partly funded the study.
Learn more about anti-clotting drugs at heart.org.
The American Heart Association logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=9940
Statements and conclusions of study authors published in American Heart Association scientific journals or presented at American Heart Association conferences are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
NR12 – 1087 (ESS/Escolar)
Additional resources are available on the right column of this link:
http://newsroom.heart.org/pr/aha/_prv-three-therapies-may-reverse-action-235393.aspx
For Media Inquiries: (214) 706-1173
Maggie Francis: (214) 706-1382; maggie.francis@heart.org
Carrie Thacker: (214) 706-1665; carrie.thacker@heart.org
Julie Del Barto (broadcast): (214) 706-1330; julie.delbarto@heart.org
For Public Inquiries: (800) AHA-USA1 (242-8721)